Appia Bio Announces Appointment of Robert S. Negrin, M.D., to Scientific Advisory Board

LOS ANGELES, Dec. 15, 2022 /PRNewswire/ -- Appia Bio, Inc., a preclinical-stage biotechnology company developing allogeneic chimeric antigen receptor natural killer T (CAR-NKT) cell therapies for cancer patients, today announced the appointment of Robert S. Negrin, M.D., to its Scientific...

Click to view original post